Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Merck & during the fourth quarter valued at approximately $1,628,824,000. Dodge & Cox bought a new position in shares of Merck & during the fourth quarter valued at approximately $821,068,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Merck & during the fourth quarter valued at approximately $252,822,000. Bank of Montreal Can increased its position in shares of Merck & by 49.7% in the first quarter. Bank of Montreal Can now owns 8,991,093 shares of the company’s stock valued at $571,295,000 after buying an additional 2,983,319 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after buying an additional 2,300,200 shares during the last quarter. 73.68% of the stock is owned by institutional investors and hedge funds.
Montecito Bank & Trust increased its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 10.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,111 shares of the company’s stock after buying an additional 1,235 shares during the period. Montecito Bank & Trust’s holdings in Merck & were worth $833,000 as of its most recent filing with the SEC.
Shares of Merck & Company, Inc. (MRK) opened at 63.92 on Wednesday. Merck & Company, Inc. has a 12-month low of $57.18 and a 12-month high of $66.80. The firm has a market capitalization of $174.83 billion, a PE ratio of 34.61 and a beta of 0.80. The firm has a 50-day moving average of $63.65 and a 200-day moving average of $63.78.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 EPS. Equities analysts anticipate that Merck & Company, Inc. will post $3.85 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.
MRK has been the subject of several research reports. Zacks Investment Research raised shares of Merck & from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a research note on Wednesday, May 10th. J P Morgan Chase & Co increased their price objective on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a research note on Thursday, May 11th. BMO Capital Markets increased their price objective on shares of Merck & from $68.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price objective for the company in a research note on Monday, May 15th. Finally, BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $69.80.
In other Merck & news, Director C Robert Kidder sold 5,000 shares of the business’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $63.54, for a total transaction of $317,700.00. Following the transaction, the director now directly owns 14,317 shares of the company’s stock, valued at approximately $909,702.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.05% of the stock is currently owned by insiders.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).